Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ANIP ANI Pharmaceuticals: Convertible Offering Leaves A Lot Of Dry Powder, Says Oppenheimer http://www.smarteranalyst.com/2014/12/08/oppenheimer-reiterates-outperform-on-ani-pharmaceuticals-shares-sees-9-upside-for-the-stock-2/
ANI Pharmaceuticals: Convertible Offering Leaves A Lot Of Dry Powder, Says Oppenheimer http://www.smarteranalyst.com/2014/12/08/oppenheimer-reiterates-outperform-on-ani-pharmaceuticals-shares-sees-9-upside-for-the-stock-2/
$TGTX Brean Capital Reiterates Buy On TG Therapeutics Following TGR-1202 Interim Data Release http://www.smarteranalyst.com/2014/12/08/brean-capital-reiterates-buy-on-tg-therapeutics-shares-sees-52-upside-for-the-stock-3/
$AAPL Apple’s Stock Has Healthy Upside Over The Next Year, Says Cantor http://www.smarteranalyst.com/2014/12/08/cantor-maintains-buy-on-apple-shares-sees-25-upside-for-the-stock/
Apple’s Stock Has Healthy Upside Over The Next Year, Says Cantor http://www.smarteranalyst.com/2014/12/08/cantor-maintains-buy-on-apple-shares-sees-25-upside-for-the-stock/
$CBST Cantor Raises Cubist Pharmaceuticals Price Target Following Merck Acquisition http://www.smarteranalyst.com/2014/12/08/cantor-maintains-hold-on-cubist-pharmaceuticals-shares-sees-11-downside-for-the-stock/
$CBST $MRK Cantor Raises Cubist Pharmaceuticals Price Target Following Merck Acquisition http://www.smarteranalyst.com/2014/12/08/cantor-maintains-hold-on-cubist-pharmaceuticals-shares-sees-11-downside-for-the-stock/
$SBUX William Blair Reiterates Outperform On Starbucks Following Biennial Investor Day http://www.smarteranalyst.com/2014/12/05/william-blair-reiterates-outperform-on-starbucks-following-biennial-investor-day/
$SBUX William Blair Reiterates Outperform On Starbucks Following Biennial Investor Day http://www.smarteranalyst.com/2014/12/05/william-blair-reiterates-outperform-on-starbucks-following-biennial-investor-day/
$FIVE Five Below: The 3Q Release Will Favor The Bears, But It Should Present A Buying Opportunity, Says UBS http://www.smarteranalyst.com/2014/12/05/five-below-the-3q-release-will-favor-the-bears-but-it-should-present-a-buying-opportunity-says-ubs/
Roth Capital Maintains Buy On Magellan Petroleum As CO2 Source Creates Opportunities http://www.smarteranalyst.com/2014/12/05/roth-capital-maintains-buy-on-magellan-petroleum-as-co2-source-creates-opportunities/
$CLDX Cowen Maintains Outperform On Celldex Following Initiation Of Phase II Trial Of Glembatumumab http://www.smarteranalyst.com/2014/12/05/cowen-maintains-outperform-on-celldex-following-initiation-of-phase-ii-trial-of-glembatumumab-in-advanced-melanoma/
$CLDX Cowen Maintains Outperform On Celldex Following Initiation Of Phase II Trial Of Glembatumumab http://www.smarteranalyst.com/2014/12/05/cowen-maintains-outperform-on-celldex-following-initiation-of-phase-ii-trial-of-glembatumumab-in-advanced-melanoma/
$ARRY William Blair Reiterates Outperform On Array Biopharma As It Regains Global Rights To Binimetinib http://www.smarteranalyst.com/2014/12/05/william-blair-reiterates-outperform-on-array-biopharma-as-it-regains-global-rights-to-binimetinib/
$ARRY William Blair Reiterates Outperform On Array Biopharma As It Regains Global Rights To Binimetinib http://www.smarteranalyst.com/2014/12/05/william-blair-reiterates-outperform-on-array-biopharma-as-it-regains-global-rights-to-binimetinib/
$INCY Cowen Maintains Outperform On Incyte Following Jakafi FDA Approval For Polycythemia Vera http://www.smarteranalyst.com/2014/12/05/cowen-maintains-outperform-on-incyte-following-jakafi-fda-approval-for-polycythemia-vera/
$INCY Cowen Maintains Outperform On Incyte Following Jakafi FDA Approval For Polycythemia Vera http://www.smarteranalyst.com/2014/12/05/cowen-maintains-outperform-on-incyte-following-jakafi-fda-approval-for-polycythemia-vera/
$CYTX Roth Capital Comments On Cytori Therapeutics Following New Japanese Regenerative Medicine Laws http://www.smarteranalyst.com/2014/12/05/roth-capital-comments-on-cytori-therapeutics-following-new-japanese-regenerative-medicine-laws/
Roth Capital Comments On Cytori Therapeutics Following New Japanese Regenerative Medicine Laws
http://www.smarteranalyst.com/2014/12/05/roth-capital-comments-on-cytori-therapeutics-following-new-japanese-regenerative-medicine-laws/
$KERX Cowen Initiates Outperform On Keryx Biopharmaceuticals, Sees 64% Upside http://www.smarteranalyst.com/2014/12/05/cowen-initiates-outperform-on-keryx-biopharmaceuticals-sees-64-upside/
$ZUMZ Roth Capital Raises Zumiez Price Target On The Heels Of Strong 3Q14 Results http://www.smarteranalyst.com/2014/12/05/roth-capital-raises-zumiez-price-target-on-the-heels-of-strong-3q14-results/
Roth Capital Maintains Buy On Celldex Following Initiation Of CDX-011 Phase II Study http://www.smarteranalyst.com/2014/12/05/roth-capital-maintains-buy-on-celldex-following-initiation-of-cdx-011-phase-ii-study/
$CLDX Roth Capital Maintains Buy On Celldex Following Initiation Of CDX-011 Phase II Study http://www.smarteranalyst.com/2014/12/05/roth-capital-maintains-buy-on-celldex-following-initiation-of-cdx-011-phase-ii-study/
$SQNM William Blair Comments On Sequenom In Light Of IP Settlement With Illumina http://www.smarteranalyst.com/2014/12/05/william-blair-comments-on-sequenom-in-light-of-ip-settlement-with-illumina/
$SQNM William Blair Comments On Sequenom In Light Of IP Settlement With Illumina http://www.smarteranalyst.com/2014/12/05/william-blair-comments-on-sequenom-in-light-of-ip-settlement-with-illumina/
$NFLX RBC Reiterates Outperform On Netflix Following Surveys Results http://www.smarteranalyst.com/2014/12/04/rbc-reiterates-outperform-on-netflix-following-surveys-results/
$NFLX RBC Reiterates Outperform On Netflix Following Surveys Results http://www.smarteranalyst.com/2014/12/04/rbc-reiterates-outperform-on-netflix-following-surveys-results/
Apple Inc. To Have An “Explosive” Quarter: JMP Analyst http://www.smarteranalyst.com/2014/12/04/apple-inc-to-have-an-explosive-quarter-jmp-analyst/
$ANF William Blair Remains Positive On Abercrombie & Fitch Despite Disappointing 3Q Results http://www.smarteranalyst.com/2014/12/04/william-blair-remains-positive-on-abercrombie-fitch-despite-disappointing-3q-results/
$ANF William Blair Remains Positive On Abercrombie & Fitch Despite Disappointing 3Q Results http://www.smarteranalyst.com/2014/12/04/william-blair-remains-positive-on-abercrombie-fitch-despite-disappointing-3q-results/
$AVGO Deutsche Bank Raises Avago Technologies Price Target As FBAR Momentum Continues http://www.smarteranalyst.com/2014/12/04/deutsche-bank-raises-avago-technologies-price-target-as-fbar-momentum-continues/
$AVGO Deutsche Bank Raises Avago Technologies Price Target As FBAR Momentum Continues http://www.smarteranalyst.com/2014/12/04/deutsche-bank-raises-avago-technologies-price-target-as-fbar-momentum-continues/
$MBLY We See Significant Upside For Mobileye Shares, Says Deutsche Bank http://www.smarteranalyst.com/2014/12/04/we-see-significant-upside-for-mobileye-shares-says-deutsche-bank/
$XOM Oppenheimer Maintains Perform On Exxon Mobil As Cash Flow Deficit Widens On Lower Oil Prices http://www.smarteranalyst.com/2014/12/04/oppenheimer-maintains-perform-on-exxon-mobil-as-cash-flow-deficit-widens-on-lower-oil-prices/
$XOM Oppenheimer Maintains Perform On Exxon Mobil As Cash Flow Deficit Widens On Lower Oil Prices http://www.smarteranalyst.com/2014/12/04/oppenheimer-maintains-perform-on-exxon-mobil-as-cash-flow-deficit-widens-on-lower-oil-prices/
$SQNM Oppenheimer Reiterates Outperform On Sequenom Following Patent Settlement With Illumina http://www.smarteranalyst.com/2014/12/04/oppenheimer-reiterates-outperform-on-sequenom-following-patent-settlement-with-illumina/
$SQNM Oppenheimer Reiterates Outperform On Sequenom Following Patent Settlement With Illumina http://www.smarteranalyst.com/2014/12/04/oppenheimer-reiterates-outperform-on-sequenom-following-patent-settlement-with-illumina/
$IBM After Three Challenging Years, We Believe Change Is Inevitable For IBM In 2015, Says Cantor http://www.smarteranalyst.com/2014/12/04/after-three-challenging-years-we-believe-change-is-inevitable-for-ibm-in-2015-says-cantor/
$IBM After Three Challenging Years, We Believe Change Is Inevitable For IBM In 2015, Says Cantor http://www.smarteranalyst.com/2014/12/04/after-three-challenging-years-we-believe-change-is-inevitable-for-ibm-in-2015-says-cantor/
$AVGO Oppenheimer Raises Avago Technologies Price Target On The Back Of F4Q Results http://www.smarteranalyst.com/2014/12/04/oppenheimer-raises-avago-technologies-price-target-on-the-back-of-f4q-results/